{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:33:25Z","timestamp":1793082805406,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.euroneuro.2024.10.006","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T22:00:40Z","timestamp":1731535240000},"page":"9-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4698-5033","authenticated-orcid":false,"given":"Guido","family":"Camm\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5071-5907","authenticated-orcid":false,"given":"Monika P.","family":"Verdouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3700-8906","authenticated-orcid":false,"given":"Pim B.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-7796","authenticated-orcid":false,"given":"Lucianne","family":"Groenink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Batalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.euroneuro.2024.10.006_bib0001","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/ja01865a080","article-title":"Isolation of Cannabinol, Cannabidiol and Quebrachitol from Red Oil of Minnesota Wild Hemp","volume":"62","author":"Adams","year":"1940","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118271","article-title":"Behavioural and molecular effects of cannabidiolic acid in mice","volume":"259","author":"Alegre-Zurano","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0003","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"issue":"8","key":"10.1016\/j.euroneuro.2024.10.006_bib0004","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/sj.npp.1300454","article-title":"Endocannabinoid system modulates relapse to methamphetamine seeking: Possible mediation by the arachidonic acid cascade","volume":"29","author":"Anggadiredja","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.euroneuro.2024.10.006_bib0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/FBP.0000000000000565","article-title":"Cannabidiol disrupts conditioned fear expression and cannabidiolic acid reduces trauma-induced anxiety-related behaviour in mice","volume":"31","author":"Assareh","year":"2020","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0008","article-title":"Autism and associated disorders: cannabis as a potential therapy","volume":"14","author":"Babayeva","year":"2022"},{"issue":"8","key":"10.1016\/j.euroneuro.2024.10.006_bib0009","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41386-019-0405-9","article-title":"The critical importance of basic animal research for neuropsychiatric disorders","volume":"44","author":"Bale","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.euroneuro.2024.10.006_bib0010","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/jcm8071058","article-title":"The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review","volume":"8","author":"Batalla","year":"2019","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.euroneuro.2024.10.006_bib0011","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11920-015-0564-2","article-title":"Psychopharmacological Strategies in the Management of Posttraumatic Stress Disorder (PTSD): What Have We Learned?","volume":"17","author":"Bernardy","year":"2015","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0012","doi-asserted-by":"crossref","DOI":"10.1007\/BF00426828","article-title":"Psycho pharmacology Effect of Some Cannabinoids on Naloxone-Precipitated Abstinence in Morphine-Dependent Mice","volume":"49","author":"Bhargava","year":"1976","journal-title":"Psychopharmacology. (Berl)"},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/0091-3057(78)90115-6","article-title":"Time Course of the Effects of Naturally Occurring Cannabinoids on Morphine Abstinence Syndrome","volume":"8","author":"Bhargava","year":"1978","journal-title":"Pharmacology Biochemistry & Behavior"},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00502","article-title":"Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials","volume":"12","author":"Bitencourt","year":"2018","journal-title":"Front. Neurosci."},{"issue":"12","key":"10.1016\/j.euroneuro.2024.10.006_bib0015","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis","volume":"6","author":"Black","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2024.10.006_bib0016","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a Potential Treatment for Anxiety Disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics."},{"issue":"6","key":"10.1016\/j.euroneuro.2024.10.006_bib0018","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/bph.12043","article-title":"Cannabidiolic acid prevents vomiting in <scp>S<\/scp>uncus murinus and nausea-induced behaviour in rats by enhancing 5- <scp>HT 1A <\/scp>receptor activation","volume":"168","author":"Bolognini","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2024.10.006_bib0019","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.pneurobio.2010.06.010","article-title":"Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia","volume":"92","author":"Bossong","year":"2010","journal-title":"Prog. Neurobiol."},{"issue":"2","key":"10.1016\/j.euroneuro.2024.10.006_bib0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00213-015-4100-1","article-title":"Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea","volume":"233","author":"Brierley","year":"2016","journal-title":"Psychopharmacology. (Berl)"},{"issue":"10","key":"10.1016\/j.euroneuro.2024.10.006_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105526","article-title":"Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence","volume":"23","author":"Bright","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.euroneuro.2024.10.006_bib0022","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.neubiorev.2008.03.012","article-title":"Models of schizophrenia in humans and animals based on inhibition of NMDA receptors","volume":"32","author":"Buben\u00edkov\u00e1-Vale\u0161ov\u00e1","year":"2008","journal-title":"Neuroscience & Biobehavioral Reviews"},{"issue":"8","key":"10.1016\/j.euroneuro.2024.10.006_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/biom12081084","article-title":"Minor Phytocannabinoids: A Misleading Name but a Promising Opportunity for Biomedical Research","volume":"12","author":"Caprioglio","year":"2022","journal-title":"Biomolecules."},{"issue":"5","key":"10.1016\/j.euroneuro.2024.10.006_bib0024","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/bph.13000","article-title":"The phytocannabinoid, \u03949-tetrahydrocannabivarin, can act through 5-HT1A receptors to produce antipsychotic effects","volume":"172","author":"Cascio","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.10.006_bib0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1476-5381.2009.00515.x","article-title":"Evidence that the plant cannabinoid cannabigerol is a highly potent \u03b1 2 -adrenoceptor agonist and moderately potent 5HT 1A receptor antagonist","volume":"159","author":"Cascio","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.10.006_bib0026","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuron.2012.09.020","article-title":"Endocannabinoid Signaling and Synaptic Function","volume":"76","author":"Castillo","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/0091-3057(85)90122-4","article-title":"The Quasi-Morphine Withdrawal Syndrome: Effect of Cannabinol, Cannabidiol and Tetrahydrocannabinol","volume":"23","author":"Chesher","year":"1985","journal-title":"Pharmacology Biochemistry & Behavior"},{"issue":"5456","key":"10.1016\/j.euroneuro.2024.10.006_bib0029","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/249471a0","article-title":"Quasi morphine-abstinence syndrome","volume":"249","author":"Collier","year":"1974","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.euroneuro.2024.10.006_bib0030","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","article-title":"The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis","volume":"29","author":"D'Souza","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.euroneuro.2024.10.006_bib0031","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","article-title":"Antidepressant-like effect of \u03949-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L","volume":"95","author":"El-Alfy","year":"2010","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0032","series-title":"Handbook of Cannabis","first-page":"3","article-title":"Constituents of Cannabis Sativa","author":"ElSohly","year":"2014"},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0033","doi-asserted-by":"crossref","unstructured":"ElSohly, M.A., Radwan, M.M., Gul, W., Chandra, S., & Galal, A. (2017). Phytochemistry of Cannabis sativa L. (pp. 1\u201336). https:\/\/doi.org\/10.1007\/978-3-319-45541-9_1.","DOI":"10.1007\/978-3-319-45541-9_1"},{"issue":"2","key":"10.1016\/j.euroneuro.2024.10.006_bib0034","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/0269881115615104","article-title":"The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial","volume":"30","author":"Englund","year":"2016","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1016\/j.euroneuro.2024.10.006_bib0035","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1017\/S0033291712001511","article-title":"Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature","volume":"43","author":"Ferrari","year":"2013","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.10.006_bib0036","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1021\/ja00730a036","article-title":"Isolation and structure of .DELTA.+- tetrahydrocannabinol and other neutral cannabinoids from hashish","volume":"93","author":"Gaoni","year":"1971","journal-title":"J. Am. Chem. Soc."},{"issue":"11","key":"10.1016\/j.euroneuro.2024.10.006_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom10111575","article-title":"Cannabidiol: A potential new alternative for the treatment of anxiety, depression, and psychotic disorders","volume":"10","author":"Garc\u00eda-Guti\u00e9rrez","year":"2020","journal-title":"Biomolecules."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.10.006_bib0038","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0269881110389095","article-title":"Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT 1A receptors","volume":"26","author":"Gomes","year":"2012","journal-title":"Journal of Psychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2024.10.006_bib0039","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00213-010-2036-z","article-title":"The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors","volume":"213","author":"Gomes","year":"2011","journal-title":"Psychopharmacology. (Berl)"},{"issue":"12","key":"10.1016\/j.euroneuro.2024.10.006_bib0040","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1039\/C6NP00074F","article-title":"Phytocannabinoids: a unified critical inventory","volume":"33","author":"Hanu\u0161","year":"2016","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2018.05.027","article-title":"Acute oral cannabidiolic acid methyl ester reduces depression-like behavior in two genetic animal models of depression","volume":"351","author":"Hen-Shoval","year":"2018","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.euroneuro.2024.10.006_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043828","article-title":"Cannabinoid Receptor 2 Blockade Prevents Anti-Depressive-like Effect of Cannabidiol Acid Methyl Ester in Female WKY Rats","volume":"24","author":"Hen-Shoval","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5\u20136","key":"10.1016\/j.euroneuro.2024.10.006_bib0043","article-title":"Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?","volume":"16","author":"Hill","year":"2005","journal-title":"Behav. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.10.006_bib0044","first-page":"185","article-title":"Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats","volume":"12","author":"Hine","year":"1975","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0045","unstructured":"Hollander, E. (2019). Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) (NCT03202303)."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.10.006_bib0046","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC. Med. Res. Methodol."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.10.006_bib0047","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/can.2016.0034","article-title":"An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies","volume":"2","author":"Iffland","year":"2017","journal-title":"Cannabis. Cannabinoid. Res."},{"issue":"6 June","key":"10.1016\/j.euroneuro.2024.10.006_bib0048","article-title":"Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications","volume":"22","author":"Ineichen","year":"2024","journal-title":"PLoS. Biol."},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2024.10.006_bib0049","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.schres.2015.01.033","article-title":"A systematic review of the antipsychotic properties of cannabidiol in humans","volume":"162","author":"Iseger","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0050","doi-asserted-by":"crossref","unstructured":"Joshi, N., & Onaivi, E.S. (2019). Endocannabinoid System Components: Overview and Tissue Distribution (pp. 1\u201312). https:\/\/doi.org\/10.1007\/978-3-030-21737-2_1.","DOI":"10.1007\/978-3-030-21737-2_1"},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0051","series-title":"Cannabinoids and Neuropsychiatric Disorders","first-page":"131","article-title":"Psychiatric Disorders and Cannabinoid Receptors","author":"Joshi","year":"2021"},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0052","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbr.2013.04.043","article-title":"Alterations in the endocannabinoid system in the rat valproic acid model of autism","volume":"249","author":"Kerr","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"S1","key":"10.1016\/j.euroneuro.2024.10.006_bib0053","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1089\/can.2023.0049","article-title":"Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats","volume":"8","author":"Kulpa","year":"2023","journal-title":"Cannabis. Cannabinoid. Res."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0054","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euroneuro.2023.04.001","article-title":"Anxiolytic effects of endocannabinoid enhancing compounds: A systematic review and meta-analysis","volume":"72","author":"Kwee","year":"2023","journal-title":"European Neuropsychopharmacology"},{"issue":"9920","key":"10.1016\/j.euroneuro.2024.10.006_bib0055","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(13)61539-1","article-title":"Autism","volume":"383","author":"Lai","year":"2014","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.euroneuro.2024.10.006_bib0056","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1369-1600.2008.00106.x","article-title":"Cannabis and psychiatric disorders: it is not only addiction","volume":"13","author":"Leweke","year":"2008","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0057","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology."},{"issue":"4","key":"10.1016\/j.euroneuro.2024.10.006_bib0058","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.tins.2006.01.008","article-title":"Involvement of the endocannabinoid system in drug addiction","volume":"29","author":"Maldonado","year":"2006","journal-title":"Trends. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0059","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jpsychires.2021.05.044","article-title":"Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials","volume":"140","author":"McKee","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"12","key":"10.1016\/j.euroneuro.2024.10.006_bib0060","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","article-title":"Hashish\u2014I: The structure of Cannabidiol","volume":"19","author":"Mechoulam","year":"1963","journal-title":"Tetrahedron."},{"issue":"3","key":"10.1016\/j.euroneuro.2024.10.006_bib0061","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1663\/0013-0001(2003)057[0295:AEFTTO]2.0.CO;2","article-title":"Archaeological evidence for the tradition of psychoactive plant use In the old world","volume":"57","author":"Merlin","year":"2003","journal-title":"Econ. Bot."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0062","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1089\/can.2023.0066","article-title":"Pharmacokinetics of Oral Minor Cannabinoids in Blood and Brain","volume":"8","author":"Moore","year":"2023","journal-title":"Cannabis. Cannabinoid. Res."},{"issue":"10","key":"10.1016\/j.euroneuro.2024.10.006_bib0063","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1017\/S0033291709005522","article-title":"The acute effects of synthetic intravenous \u03949-tetrahydrocannabinol on psychosis, mood and cognitive functioning","volume":"39","author":"Morrison","year":"2009","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0064","series-title":"The Health Effects of Cannabis and Cannabinoids","year":"2017"},{"issue":"3","key":"10.1016\/j.euroneuro.2024.10.006_bib0065","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.pbb.2012.10.008","article-title":"Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability","volume":"103","author":"O'Brien","year":"2013","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0066","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0067","series-title":"Handbook of Cannabis","first-page":"189","article-title":"Effects of Phytocannabinoids on Anxiety, Mood, and the Endocrine System","author":"Patel","year":"2014"},{"issue":"2","key":"10.1016\/j.euroneuro.2024.10.006_bib0068","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.10.006_bib0069","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bph.14073","article-title":"Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT 1A receptor-mediated suppression of nausea and anxiety in rats","volume":"175","author":"Pertwee","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"S1","key":"10.1016\/j.euroneuro.2024.10.006_bib0071","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1089\/can.2023.0038","article-title":"A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral \u0394 8 -Tetrahydrocannabivarin in Healthy Participants","volume":"8","author":"Peters","year":"2023","journal-title":"Cannabis. Cannabinoid. Res."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0072","unstructured":"R Core Team. (2024). R: A Language and Environment for Statistical Computing."},{"issue":"4","key":"10.1016\/j.euroneuro.2024.10.006_bib0073","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/bph.14895","article-title":"A time-dependent contribution of hippocampal CB 1, CB 2 and PPAR\u03b3 receptors to cannabidiol-induced disruption of fear memory consolidation","volume":"177","author":"Raymundi","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2024.10.006_bib0074","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3934\/Neuroscience.2021022","article-title":"Cannabis in the Management of PTSD: a Systematic Review","volume":"8","author":"Rehman","year":"2021","journal-title":"AIMS. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0076","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neuroscience.2011.11.057","article-title":"Fear relief\u2014toward a new conceptual frame work and what endocannabinoids gotta do with it","volume":"204","author":"Riebe","year":"2012","journal-title":"Neuroscience"},{"issue":"16","key":"10.1016\/j.euroneuro.2024.10.006_bib0077","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s00213-014-3498-1","article-title":"A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping","volume":"231","author":"Rock","year":"2014","journal-title":"Psychopharmacology. (Berl)"},{"issue":"14","key":"10.1016\/j.euroneuro.2024.10.006_bib0079","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s00213-017-4626-5","article-title":"Effect of prior foot shock stress and \u03949-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats","volume":"234","author":"Rock","year":"2017","journal-title":"Psychopharmacology. (Berl)"},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2016.00422","article-title":"Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence","volume":"7","author":"Rohleder","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0081","doi-asserted-by":"crossref","unstructured":"Russo, E.B., & Marcu, J. (2017). Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads (pp. 67\u2013134). https:\/\/doi.org\/10.1016\/bs.apha.2017.03.004.","DOI":"10.1016\/bs.apha.2017.03.004"},{"issue":"1","key":"10.1016\/j.euroneuro.2024.10.006_bib0082","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-019-2409-8","article-title":"Medicinal cannabis for psychiatric disorders: A clinically-focused systematic review","volume":"20","author":"Sarris","year":"2020","journal-title":"BMC. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2024.10.006_bib0083","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3934\/molsci.2019.1.27","article-title":"Endocannabinoid system involvement in autism spectrum disorder: An overview with potential therapeutic applications","volume":"6","author":"Schultz","year":"2019","journal-title":"AIMS. Mol. Sci."},{"issue":"2","key":"10.1016\/j.euroneuro.2024.10.006_bib0084","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000443890","article-title":"Prohedonic Effect of Cannabidiol in a Rat Model of Depression","volume":"73","author":"Shoval","year":"2016","journal-title":"Neuropsychobiology."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0085","doi-asserted-by":"crossref","DOI":"10.47626\/2237-6089-2020-0149","article-title":"Cannabis and cannabinoid use in autism spectrum disorder: a systematic review","author":"Silva Junior","year":"2022","journal-title":"Trends. Psychiatry PsychOther"},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0086","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.neuropharm.2017.07.024","article-title":"Cannabidiol disrupts the consolidation of specific and generalized fear memories via dorsal hippocampus CB1 and CB2 receptors","volume":"125","author":"Stern","year":"2017","journal-title":"Neuropharmacology."},{"issue":"9","key":"10.1016\/j.euroneuro.2024.10.006_bib0087","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/npp.2012.63","article-title":"On Disruption of Fear Memory by Reconsolidation Blockade: Evidence from Cannabidiol Treatment","volume":"37","author":"Stern","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0088","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"The BMJ"},{"issue":"19","key":"10.1016\/j.euroneuro.2024.10.006_bib0089","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1111\/bph.15185","article-title":"A systematic review of minor phytocannabinoids with promising neuroprotective potential","volume":"177","author":"Stone","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.euroneuro.2024.10.006_bib0090","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00213-022-06119-3","article-title":"Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses","volume":"239","author":"Umpierrez","year":"2022","journal-title":"Psychopharmacology. (Berl)"},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0091","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.777804","article-title":"Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses","volume":"12","author":"Walsh","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"24","key":"10.1016\/j.euroneuro.2024.10.006_bib0092","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1111\/bph.14844","article-title":"\u03948-Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence","volume":"176","author":"Xi","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/S0006-8993(01)02655-5","article-title":"Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice a a b c c","volume":"909","author":"Yamaguchi","year":"2001","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.10.006_bib0095","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77175-y","article-title":"In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa","volume":"10","author":"Zagzoog","year":"2020","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.euroneuro.2024.10.006_bib0096","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3390\/ijms18091916","article-title":"The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models","volume":"18","author":"Zamberletti","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.euroneuro.2024.10.006_bib0097","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2019.00367","article-title":"Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats","volume":"13","author":"Zamberletti","year":"2019","journal-title":"Front. Cell Neurosci."},{"issue":"3","key":"10.1016\/j.euroneuro.2024.10.006_bib0098","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1089\/can.2021.0027","article-title":"The Cannabis Constituent Cannabigerol Does Not Disrupt Fear Memory Processes or Stress-Induced Anxiety in Mice","volume":"7","author":"Zhou","year":"2022","journal-title":"Cannabis. Cannabinoid. Res."},{"issue":"3","key":"10.1016\/j.euroneuro.2024.10.006_bib0100","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System","volume":"19","author":"Zou","year":"2018","journal-title":"Int. J. Mol. Sci."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24007508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24007508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T10:05:51Z","timestamp":1738058751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X24007508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":91,"alternative-id":["S0924977X24007508"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.10.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}